Iconovo announce that the capsule-based dry powder inhaler ICOcap™ is CE-marked for use in clinical trials. ICOcap™ is now available for customers to use in clinical trials that develop capsule-based formulations and can be bought from Stevanato, the manufacturing and distribution partner of Iconovo. The CE mark is applied in conformity with the requirements of Directive 93/42/EEC as a Class 1 Medical Device in collaboration with our partners Stevanato Group and their affiliate Balda Medical GmbH.
”Getting the CE certification mark for ICOcap™ takes Iconovo and Stevanato one step closer to commercial sales of this uniquely designed capsule inhaler. The inhaler can now be sold for use in clinical trials. This is not only of importance for Europe but also for the rest of the world since the CE marking globally is considered as a sign of quality.” says Johan Wäborg, CEO for Iconovo.
ICOcap is a robust capsule-based dry powder inhaler with a unique grip-friendly hinge design that ensures ease of use. It is currently designed with a low flow resistance but can be customized to a flow resistance of choice. ICOcap™ is available from Stevanato for quick product launch and competitively priced off-the-shelf supply.